Utility of serum YKL-40 as a tumor-specific marker of hepatobiliary malignancies

Gut and Liver

Volumn 4, Issue 4, 2010, Pages 537-542

  Yang, Ju Dong ^a   Kim, Eugene ^a   Pedersen, Rachel A ^b   Kim, W Ray ^a   Pungpapong, Surakit ^a   Roberts, Lewis R ^a  

^a MAYO CLINIC   (United States)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

Cholangiocarcinoma; End stage liver disease; Hepatocellular carcinoma; Model for end stage liver disease; YKL 40

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; TUMOR MARKER; UNCLASSIFIED DRUG; YKL 40;

ADULT; ARTICLE; BILE DUCT CARCINOMA; BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; END STAGE LIVER DISEASE; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREVALENCE;

EID: 78650675634     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2010.4.4.537     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006;53:172-209.
3. Michelsen AE, Rathcke CN, Skjelland M, et al. Increased YKL-40 expression in patients with carotid atherosclerosis. Atherosclerosis 2010;211:589-595.
4. Zheng JL, Lu L, Hu J, et al. Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease. Atherosclerosis 2010;210:590-595.
5. Rathcke CN, Persson F, Tarnow L, Rossing P, Vestergaard H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care 2009; 32:323-328.
6. Nielsen AR, Erikstrup C, Johansen JS, et al. Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes 2008;57:3078-3082.
7. Letuve S, Kozhich A, Arouche N, et al. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol 2008;181:5167-5173.
8. Chupp GL, Lee CG, Jarjour N, et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 2007;357:2016-2027.
9. Erzin Y, Uzun H, Karatas A, Celik AF. Serum YKL-40 as a marker of disease activity and stricture formation in patients with Crohn's disease. J Gastroenterol Hepatol 2008; 23:e357-362.
10. Huang K, Wu LD. YKL-40: a potential biomarker for osteoarthritis. J Int Med Res 2009;37:18-24.
11. Bi J, Lau SH, Lv ZL, et al. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol 2009;40:1790-1797.
12. Shao R, Hamel K, Petersen L, et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009; 28:4456-4468.
13. Lau SH, Guan XY. Cytogenetic and molecular genetic alterations in hepatocellular carcinoma. Acta Pharmacol Sin 2005;26:659-665.
14. Mehta P, Ploutz-Snyder R, Nandi J, Rawlins SR, Sanderson SO, Levine RA. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2008; 103:928-936.
15. Johansen JS, Christoffersen P, Moller S, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000;32:911-920.
16. Saitou Y, Shiraki K, Yamanaka Y, et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005;11:476-481.
17. Nojgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003;39:179-186.
18. Lee KG, Seo YS, An H, et al. Usefulness of non-invasive markers for predicting liver cirrhosis in patients with chronic hepatitis B. J Gastroenterol Hepatol 2010;25:94-100.
19. Cintin C, Johansen JS, Christensen IJ, Price PA, Sorensen S, Nielsen HJ. Serum YKL-40 and colorectal cancer. Br J Cancer 1999;79:1494-1499.
20. Johansen JS, Christensen IJ, Riisbro R, et al. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res Treat 2003;80:15-21.
21. Johansen JS, Drivsholm L, Price PA, Christensen IJ. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 2004;46:333-340.
22. Roslind A, Johansen JS, Christensen IJ, et al. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Int J Cancer 2008;122:857-863.
23. Brasso K, Christensen IJ, Johansen JS, et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 2006;66:503-513.
24. Dehn H, Hogdall EV, Johansen JS, et al. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet Gynecol Scand 2003;82:287-293.
25. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 2006;106:1130-1139.
26. Johansen JS, Jensen BV, Roslind A, Price PA. Is YKL-40 a new therapeutic target in cancer? Expert Opin Ther Targets 2007;11:219-234.
27. Johansen JS, Bojesen SE, Mylin AK, Frikke-Schmidt R, Price PA, Nordestgaard BG. Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol 2009;27:572-578.
28. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 2002;62:4364-4368.
29. Lau SH, Sham JS, Xie D, et al. Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 2006;25:1242-1250.
30. Franceschi C, Bonafe M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000;908:244-254.
31. Johansen JS, Pedersen AN, Schroll M, Jorgensen T, Pedersen BK, Bruunsgaard H. High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality. Clin Exp Immunol 2008;151:260-266.